Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

Inclusion Criteria: * Type 2 diabetes subjects between the ages of 30 and 80 years of age, inclusive, at Screening * Hemoglobin A1c (HbA1c) ≤10.0% at screening * Male or female (female of child bearing age must use definitive contraceptive therapy) * Type 2 Diabetes Mellitus subjects on a stable anti-diabetes regimen of diet and/or metformin alone therapy or on metformin plus an insulin secretion enhancer (sulfonylureas, dipeptidyl peptidase 4 (DPP4) Inhibitors, Glucagon-like peptide (GLP-1) analogs) therapy for a 60 day period prior to randomization. Subjects with diabetes duration of ≥ 4 years must be using an insulin secretion enhancer (e.g. sulphonylureas (SU), DPP4, GLP-1 analog). Subjects must have a documented C-peptide level (either fasting or random) of \>2 ng/ml from the screening visit. Exclusion Criteria: * Presence of type 1 diabetes mellitus (defined as C-peptide \<1 ng /ml) * Type 2 diabetes mellitus subjects on insulin. * Use of prescription sympathomimetics, ergot alkaloid derivatives, or anti-migraine medications, dopamine2 (D2)-like receptor antagonists (e.g. metoclopramide, domperidone) or systemic corticosteroids * Uncontrolled hypertension (systolic BP \>160 or diastolic BP \> 100 at screening) or a history of orthostatic hypotension * History of significant gastroparesis * Presence of diabetic retinopathy that is more severe than "background" level * Presence of diabetic nephropathy, or renal impairment defined by blood urea nitrogen (BUN) \>40mg/dl …